Correction to: Simulations to predict clinical trial outcome of bevacizumab plus chemotherapy vs. chemotherapy alone in patients with first‐line gastric cancer and elevated plasma VEGF‐A
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGastric Cancer Management and Outcomes · Cholangiocarcinoma and Gallbladder Cancer Studies · Colorectal Cancer Treatments and Studies
Han, K., Claret, L., Piao, Y., Hegde, P., Joshi, A., Powell, J., Jin, J. and Bruno, R. (2016), Simulations to predict clinical trial outcome of bevacizumab plus chemotherapy vs. chemotherapy alone in patients with first‐line gastric cancer and elevated plasma VEGF‐A. CPT Pharmacometrics Syst. Pharmacol., 5: 352–358. https://doi.org/10.1002/psp4.12064
The first author of this paper, K. Han, should be listed as Kelong Han.